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ABSTRACT
Motivation: Genome-wide association studies are commonly used
to identify possible associations between genetic variations and
diseases. These studies mainly focus on identifying individual single
nucleotide polymorphisms (SNPs) potentially linked with one disease
of interest. In this work, we introduce a novel methodology that
identiﬁes similarities between diseases using information from a large
number of SNPs. We separate the diseases for which we have
individual genotype data into one reference disease and several
query diseases. We train a classiﬁer that distinguishes between
individuals that have the reference disease and a set of control
individuals. This classiﬁer is then used to classify the individuals that
have the query diseases. We can then rank query diseases according
to the average classiﬁcation of the individuals in each disease set,
and identify which of the query diseases are more similar to the
reference disease. We repeat these classiﬁcation and comparison
steps so that each disease is used once as reference disease.
Results: We apply this approach using a decision tree classiﬁer to
thegenotypedataofsevencommondiseasesandtwosharedcontrol
sets provided by the Wellcome Trust Case Control Consortium.
We show that this approach identiﬁes the known genetic similarity
between type 1 diabetes and rheumatoid arthritis, and identiﬁes a
new putative similarity between bipolar disease and hypertension.
Contact: seraﬁm@cs.stanford.edu
1 INTRODUCTION
Genome-wide association studies (GWAS) are an increasingly
popular approach for identifying associations between genotype and
phenotype. A large number of such studies have been performed
recently to try to identify the genetic basis of a wide variety of
diseases, and explore how this genetic basis differs depending on
the geographic origin of the studied population. High-throughput
genotyping chips are used to obtain the genotype of an individual at
several hundreds of thousands of single nucleotide polymorphisms
(SNPs). These sets of SNPs are able to represent most of the
variabilityatthesinglelocuslevelthatwasidentiﬁedbytheHapMap
project (Frazer et al., 2007). In a GWAS study, several thousands
of disease individuals, and several thousands of healthy controls
are genotyped. Statistical tests are used to identify SNPs that show
a strong association with the disease. Strong association between
a SNP and a disease can be evidence that the SNP is related to
∗To whom correspondence should be addressed.
the disease, or that it is in linkage disequilibrium with SNPs that
are related to the disease. In both cases signiﬁcant associations
provide promising leads for further experimental investigation into
the genetic etiology of diseases. These studies have led to the
identiﬁcation of more than 150 risk loci in more than 60 diseases
(Manolio and Collins, 2009). The Wellcome Trust Case-Control
Consortium (WTCCC) genotype 500000 SNPs in seven common
diseases: type 1 diabetes (T1D), type 2 diabetes (T2D), coronary
artery disease (CAD), Crohn’s disease (CD), bipolar disease (BD),
hypertension (HT) and rheumatoid arthritis (RA) (WTCCC, 2007).
In this article we use the individual genotype data from this study.
Computational methods have been used to identify disease
similarities using a variety of data sources, including gene
expression in cancer (Rhodes et al., 2004) and known relationships
between mutations and phenotypes (Goh et al., 2007). However,
while a large number of GWAS focusing on individual diseases
have been recently published, the attempts to integrate the results
of multiple studies have been limited. Most of these integration
approaches focus on combining multiple studies of the same disease
in order to increase the statistical power (Zeggini et al., 2008),
or use data from other high-throughput measurement modalities
to improve the results of GWAS studies (Chen et al., 2008).
Comparison between the genetic components of diseases have been
done using four different approaches. The ﬁrst approach is based
on the identiﬁcation of the association between one SNP in two
different diseases in two independent studies. The second approach
selects a group of SNPs that have been previously associated
with some disease and tests if they are also associated with a
different disease. An example of this approach is the genotyping
of a large number of individuals with T1D at 17 SNPs that have
been associated with other autoimmune diseases, which leads to
the identiﬁcation of a locus previously associated with only RA
as being signiﬁcantly associated with T1D as well (Fung et al.,
2009). The third approach pools data from individuals with several
diseases prior to the statistical analysis, and has been used in
the original WTCCC study. Several similar diseases (autoimmune
diseases, metabolic and cardiovascular diseases) are grouped in
order to increase the statistical power for identifying SNPs that are
signiﬁcantly associated with all the diseases in the pool. The fourth
approach compares the results of multiple GWAS, and has been
previously applied to the WTCCC dataset (Torkamani et al., 2008).
They use the P-values indicating the signiﬁcance of the association
between a SNP and a single disease, and compute the correlations
between these P-values in pairs of diseases, as well as the size of the
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intersection of the 1000 most signiﬁcant SNPs in pairs of diseases.
They identify strong similarities betweenT1D and RA, between CD
and HT, and between BD and T2D.
Inthiswork,weintroduceanovelapproachtoidentifysimilarities
in the genetic architecture of diseases. We train a classiﬁer that
distinguishes between a reference disease and the control set. We
thenusethisclassiﬁertoclassifyalltheindividualsthathaveaquery
disease. If there is a similarity at the genetic level between the query
disease and the reference disease, we expect more individuals with
the query disease to be classiﬁed as belonging to the disease class
thanifthereisnosimilarity.Wegeneralizeourproceduretomultiple
disease comparison: given a set of multiple diseases, we use each
in turn as the reference disease while treating all others as query
diseases.
There are two main differences between our new approach and
existing analyses. First, previous approaches [such as Torkamani
et al. (2008)] compute a signiﬁcance score for each SNP, and then
use these scores for comparing diseases. In our approach, we ﬁrst
compute a classiﬁcation for each individual, and then compare
diseases using these classiﬁcations. Second, we train the classiﬁer
using information from all SNPs, and during this learning process
select the SNPs that contribute to the classiﬁcation based on the
genotype data only. This genome-wide approach makes it possible
to see the classiﬁer as a statistical representation of the differences
between the disease set and the control set.
The use of classiﬁers in the context of GWAS has been
limited so far. In particular, attempts at using them for predicting
outcome based on genotype have been unsuccessful. For example,
a recent prospective study in T2D (Meigs et al., 2008) found
that using 18 loci known to be associated with T2D in a logistic
regression classiﬁer together with known phenotypic risk factors
does not signiﬁcantly improve the risk classiﬁcation, and leads to a
reclassiﬁcation in only 4% of the patients. A particular challenge
in the context of outcome prediction is that the prevalence of
most diseases is relatively low and that it is therefore necessary
to achieve high precision in order for the classiﬁer to be usable. Our
goal is not predicting individual outcomes, and we only compare
predictions made by a single classiﬁer. We can therefore ignore
disease prevalence.
A second challenge in the use of a classiﬁcation approach
for ﬁnding disease similarities is that the classiﬁer does not
explicitly identify genetic features of the disease, but rather learns to
distinguish the disease set from the control set. Differences between
the two sets that are due to other factors might therefore lead
to incorrect results. In most GWAS, a careful choice of matched
controls limits this risk. However, when using a classiﬁer trained
on one GWAS to classify individuals from a different study, there
is a risk that the background distribution of SNPs is very different
between the populations in which the datasets have been collected,
which could lead to errors, particularly when comparing diseases
using datasets from different geographic origins. This risk can be
limited by using disease data from a single source. In this work,
we use genotype data provided by the WTCCC study, in which
all individuals were living in Great Britain and individuals with
non-Caucasian ancestry were excluded.
Inthisarticle,weﬁrstprovideadetaileddescriptionoftheanalysis
approach. We then show that we are able to train classiﬁers that
achieve a classiﬁcation error that is clearly below the baseline
error for T1D, T2D, BD, HT and CAD. We use these classiﬁers
to identify strong similarities between T1D and RA, as well as
between HT and BD, and weak similarities between T1D and both
BD and HT. We also show that we are able to train a classiﬁer
that distinguishes between the two control sets in the WTCCC data.
We use this classiﬁer to identify similarities between some diseases
and individual control sets. This ﬁnding matches observations made
duringthequalitycheckphaseoftheoriginalstudy.Theimplications
of this ﬁnding on our approach are addressed in the Section 5.
Finally, we discuss the implications of the similarities we ﬁnd, and
propose extensions of this approach. A detailed description of the
dataset used in this work, the data pre-processing, the decision tree
classiﬁer and the comparison procedure are provided in Sections 3
and 4, respectively, at the end of the article.
2 APPROACH
In this section, we deﬁne the general classiﬁer-based approach to
identify genetic similarities between diseases. The approach can be
separated into four steps: data collection, preprocessing, classiﬁer
training and disease comparison. Figure 1 provides an overview of
the training and comparison steps.
The data collection step consists of collecting samples from
individuals with several diseases, as well as matched controls, and
genotyping them. Alternatively, existing data can be reanalysed.
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Fig. 1. Overview of the approach. This ﬁgure presents the classiﬁcation and
comparison steps of our analysis pipeline. These steps are repeated using
a different reference disease each time. The classiﬁer returns a real value
between 0.0 and 1.0 which we call disease-class probability. The histograms
represent the distribution of the disease-class probability of the individuals
with the reference disease (left) and of the controls (right). In the situation
depicted in this ﬁgure, there is evidence that query disease C is more similar
to the reference disease than the other query diseases.
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In both cases, it is important to limit the differences between the
disease sets and the control sets that are not related to the disease
phenotype. Similarly, differences between the different disease sets
should also be limited. In particular, it is recommended to use
individuals with the same geographic origin, the same ancestry, and
a single genotyping technology for the whole study. In this work,
we use existing data from the WTCCC which satisﬁes these criteria.
In the preprocessing step, the data are ﬁltered and uncertain
genotype measurements, as well as individuals and SNPs that do
not ﬁt quality requirements are discarded. It is important to develop
preprocessing steps that ensure good data quality. Approaches that
analyze each SNP individually can afford to have a more stringent,
often manual post-processing step on the relatively few SNPs that
show strong association. The SNPs that do not pass this quality
inspection can be discarded without affecting the results obtained
on other SNPs. In our approach however, classiﬁer training is done
using genome-wide information, and removing even a single SNP
used by the classiﬁer could potentially require retraining the entire
classiﬁer. It is therefore impractical to perform any kind of post-
processing at the SNP level. The Section 3 of this article describes
the data used in this work, as well as the quality control measures
we take.
The classiﬁer training and comparison steps are interleaved. We
start with a list of diseases and a set of individual genotypes for
each disease, as well as at least one set of control genotypes. We
pick one disease as reference disease, and refer to the remaining
diseases as query diseases. We train a classiﬁer distinguishing the
corresponding disease set from the control set. For any individual,
thisclassiﬁercouldeitherreturnabinaryclassiﬁcation(withvalues0
and 1 indicating that the classiﬁer believes the individual is part of,
respectively, the controls class or the disease class) or a continuous
value between 0 and 1. This continuous value can be seen as
the probability of the individual to be part of the disease class,
as predicted by the classiﬁer. We refer to this value as disease-
class probability. For simplicity, we will only use the disease-class
probability values for the rest of this section, but the comparison
step can be performed similarly using binary classiﬁcations. During
the comparison step, we classify individuals from the query disease
sets using the classiﬁer obtained in the training step, and for each
query disease, compute the average disease-class probability. The
training and comparison steps are then repeated so that each disease
is used once as reference disease.
We can compare the average disease-class probability of the
different query diseases to identify similarities between them.
Diseases that have a higher average disease-class probability are
more likely to be similar to the reference disease than diseases with
a lower average disease-class probability. Using cross-validation,
we can obtain the average disease-class probability of the reference
disease set and the control set used for training the classiﬁer, and
compare them with the values of the other diseases. One particular
caveat that needs to be considered in this analysis is that while the
classiﬁerdoesdistinguishthecontrolsetfromthediseaseset,thereis
no guarantee that it will only identify genetic features of the disease
set. It is also possible that it will identify and use characteristics
of the training set, especially if there are data quality issues. This
case can be identiﬁed during the comparison step if the average
disease-class probability of most query diseases is close to the
average disease-class probability of the reference disease, but very
differentfromtheaveragedisease-classprobabilityofthecontrolset.
It is therefore important to look at the distribution of the average
disease-class probabilities of all query diseases before concluding
that an individual disease is similar to the reference disease.
It is important to note that the disease-class probability of a given
individual does not correspond to the probability of this individual
actually having the disease. The disease frequency is signiﬁcantly
higher in the datasets we use for training the classiﬁer than in the
realpopulation. Inamachinelearningprobleminwhichthetestdata
are class-imbalanced, training is commonly done on class-balanced
data,andclasspriorsarethenusedtocorrectfortheimbalance.Such
priors would, however, scale all probabilities linearly, and would not
affecttherelationshipsweidentify,northeirsigniﬁcance.Estimating
the probability of an individual having the disease is not the goal of
this project and we can therefore ignore class priors.
A large variety of classiﬁers can be integrated into the analysis
pipeline used in our approach.The Section 4 provides a more formal
descriptionoftheclassiﬁcationtask.Inthisarticle,weuseacommon
classiﬁer, decision trees, to show that this approach allows us to
identify similarities. The speciﬁc details about the decision tree
classiﬁer, and how its outputs are used in the analysis step are
described in the Section 4.
3 RESULTS
We evaluate the ability of our analysis approach to identify
similaritiesbetweendiseasesusingthesetofsevendiseasesprovided
by the WTCCC. In this section, we ﬁrst evaluate the performance
of individual classiﬁers that distinguish one disease from the
joint control set. We then show that these classiﬁers can identify
similarities between diseases. Finally, we use our classiﬁer to
identify differences between the two control sets, and provide
evidence indicating that these differences do not affect the disease
similarities we identify.
3.1 Classiﬁer performance
We ﬁrst train one classiﬁer for each disease using both the 58C
and the UKBS sets as controls. The performance of each classiﬁer
is evaluated using cross-validation, and reported in Table 1. We
compare our classiﬁer to a baseline classiﬁer that classiﬁes all
individuals into one class without using the SNP data at all. The
best error such a classiﬁer can achieve during cross-validation is the
Table 1. Classiﬁer performance (cross-validation)
Disease Baseline
(%)
Error
(%)
Precision
(%)
Recall
(%)
 p Leaves
T1D 40.05 22.93 71.65 70.71 0.383 9
RA 38.43 33.45 59.12 42.09 0.130 12
BD 38.24 33.59 62.60 30.18 0.087 11
HT 39.92 36.77 57.98 28.64 0.080 12
CAD 39.05 36.62 55.25 32.73 0.075 12
T2D 39.5 38.0 54.12 25.05 0.052 14
CD 36.63 36.28 29.83 18.43 0.046 11
Baseline corresponds to the baseline error; Error, Precision and Recall to the cross-
validation performance of the decision tree classiﬁer;  p to the difference between
the average disease-class probability of the control set and the average disease-class
probability of the disease set; and Leaves to the maximum number of leaves in the
pruned classiﬁers for this disease.
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frequency of the smaller class in the training set. We refer to this
value as the baseline error.
The disease for which the classiﬁer performs best is T1D, with
a classiﬁcation error of 22.93%, compared with a baseline error
of 40.05%. The classiﬁcation error obtained by the decision tree
classiﬁer is also below the baseline error for several other diseases,
although by a substantially smaller margin. This is the case for
RA (with an error of 33.45% versus 38.43%), BD (33.59% versus
38.24%), HT (36.77% versus 39.92%) and CAD (36.62% versus
39.05%).Fortwodiseases,T2DandCD,theimprovementcompared
with the baseline error is only minimal, and we choose not to
use these classiﬁers in our analysis. While the classiﬁers that we
keep only provide small improvements in terms of classiﬁcation
error (with the exception of T1D), they have a signiﬁcantly better
trade-off between precision (at least 55%) and recall (at least 28%)
than the baseline classiﬁer (which would classify all individuals as
controls).
We do not use these classiﬁers in a binary way, but rather use
the disease-class probability, which is the conditional probability
of an individual to be part of the disease-class given its genotype,
under the model of the reference disease learned by the classiﬁer
(see Section 7 for a precise deﬁnition for decision trees). It is
thereforeinterestingtoconsiderthedistributionsofthedisease-class
probability, as obtained during cross-validation. Figure 2 illustrates
that these distributions differ signiﬁcantly for T1D. It can also be
seenthatthereareindividualsforwhichthedisease-classprobability
iscloseto50%,meaningthatthereareleafnodesintheclassiﬁerthat
represent subsets of the data that cannot be distinguished well. Our
approach takes this into account by using disease-class probabilities
rather than binary classiﬁcations. In order to evaluate the ability of
our classiﬁers to distinguish between the disease set and the control
set using the disease-class probability metric, we use the difference
 p of the average disease-class probability between the two sets.
The classiﬁers that we keep all have values of  p above 0.075. This
illustrates that while there are only small improvements in binary
classiﬁcation performance, the classiﬁers are able to distinguish
between the disease set and the control set in the way we intend
to use them.
3.2 Disease similarities
For each of the ﬁve classiﬁers with sufﬁciently good performance,
we compute the average disease-class probability of each of the
six query diseases. In summary, we identify strong symmetrical
similarities between T1D and RA, as well as between BD and HT.
Furthermore, we ﬁnd that T1D is closer to both BD and HT than
other diseases, even though we did not ﬁnd the symmetrical relation
usingtheT1Dclassiﬁer.Thissectionprovidesadetailedpresentation
of these results.
For T1D, the average disease-class probability for the control
set and the disease set, as computed using cross-validation, are
0.259 and 0.642, respectively. Figure 2 shows the distribution of
the average disease-class probabilities for the query diseases. RA,
another autoimmune disease, is clearly the closest to T1D (average
disease-class probability of 0.337). This result is signiﬁcant, with
P-value <10−5 (see the Section 4 for details on how P-values
are obtained). All other diseases have an average disease-class
probability that is close to that of the control set, which means that
there is no evidence of similarity with T1D.
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Fig. 2. Distribution of the disease-class probabilities for the T1D classiﬁer.
The two histograms show the distribution of the disease-class probability of
the individuals, respectively, in the joint control set (top) and in the T1D
set (bottom), as computed during cross-validation. The red lines represent
the average disease-class probabilities, and the black line indicates the 0.5
probability cut-off used for binary classiﬁcation. The plot in between the
histograms shows the average disease-class probabilities of the six other
diseases on the interval between the average disease-class probabilities of
the control set and of the disease set.
For RA, the average disease-class probabilities are 0.303 for
the control set and 0.433 for the disease set. The distribution of
the average disease-class probabilities for the other diseases are
shown on Figure 3a. We can observe that T1D (average disease-
class probability of 0.397) is closest to RA (P<10−5), meaning
that we ﬁnd a symmetrical similarity between the two diseases. All
other diseases have an average disease-class probability close to the
one of the control set.
For BD, the average disease-class probabilities are 0.297 for the
control set and 0.384 for the disease set. The distribution of the
average disease-class probabilities for the query diseases are shown
in Figure 3b. We can observe that there is a wider spread in the
average disease-class probabilities, and that there is no cluster of
diseases close to the control set. We can also observe that HT
(average disease-class probability of 0.359, P<10−5) is closest to
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Fig. 3. Disease-class probabilities comparisons. The plots represent the
interval between the average disease-class probabilities of the control set
and of the disease set for RA(a), BD (b), HT (c) and CAD (d), respectively.
The average disease-class probabilities for all the query diseases are shown
in blue on every plot. Note that while all plots on this ﬁgure use the same
scale, different scales are used for the central plots of ﬁgures 2 and 4.
BD, followed by T1D (average disease-class probability of 0.354,
P-value of 0.001).
For HT, the average disease-class probabilities are 0.315 for
the control set and 0.395 for the disease set. The distribution of
the average disease-class probabilities for the other diseases are
shown in Figure 3c. We can observe that BD (average disease-class
probability of 0.381, P-value <10−5) is clearly closest to HT. T1D
(average disease-class probability of 0.368, P<10−5) is also closer
to HT than the remaining diseases.
For CAD the average differences between the query diseases are
smaller than for all the other classiﬁers (Fig. 3d). Furthermore,
the classiﬁer for CAD is the one with the worst performance
amongst the ones we use in the comparison phase. Therefore,
we believe that the results are not strong enough to report
putativesimilaritiesidentiﬁedusingthisclassiﬁer,eventhoughsome
differences between diseases have signiﬁcant P-values.
Table 2. Separate training set classiﬁer performance
Experiment Baseline
(%)
Error
(%)
Precision
(%)
Recall
(%)
 p Leaves
UKBS/58C 49.62 41.15 58.33 64.05 0.093 11
R1/R2 50.03 49.45 50.59 46.42 −0.003 11
UKBS/T1D 42.62 23.15 79.53 80.34 0.402 8
58C/T1D 42.99 24.46 76.60 82.22 0.370 8
UKBS/RA 44.29 36.42 66.21 70.72 0.144 10
58C/RA 44.66 38.11 64.89 67.83 0.135 9
Baseline corresponds to the baseline error; Error, Precision and Recall to the cross-
validation performance of the decision tree classiﬁer;  p to the difference between
the average disease-class probability of the control set, and the average disease-class
probability of the disease set; and Leaves to the maximum number of leaves in the
pruned classiﬁers for this experiment. R1 and R2 represent two random splits of the
joint control set.
3.3 Differences between control sets
TheoriginalWTCCCstudyfoundseveralSNPsthataresigniﬁcantly
associated with one of the two control sets. These SNPs are ﬁltered
outduringpreprocessing,bothintheWTCCCstudyandinthiswork.
However,themereexistenceofdifferencesbetweentwocontrolsets
prompted the question whether a classiﬁer could distinguish the two
sets, and if so, what the implications of this ﬁnding would be on the
validity of results obtained with these control sets.
We perform several experiments using the two control sets
separately, and report the results in Table 2. First, we train a
control–controlclassiﬁer thatdistinguishesthetwocontrolsetsfrom
each other. This classiﬁer achieves an error of 41.15% compared
with a baseline error of 49.62%, and a  p of 0.093. This shows
that we are able to distinguish to some extent between the two
control sets. Figure 4 shows the distribution of the 58C class
probability (which corresponds to the value called disease-class
probability when the classiﬁer distinguishes between one disease
and the controls). In order to verify that this result is due to
differencesbetweenthetwospeciﬁccontrolset,andnottheabilityof
our classiﬁer to distinguish between any two sets, we randomly split
all control individuals into two sets, R1 and R2. We train a classiﬁer
todistinguishbetweenthesetwosets.Weﬁndthatthisclassiﬁerdoes
only minimally improves the classiﬁcation error (error of 49.45%,
baseline error of 50.03%,  p of −0.003).
We apply the comparison step of our pipeline using the control–
controlclassiﬁerinordertoidentifypossiblesimilaritiesbetweenthe
diseasesetandoneofthecontrolsets.Figure4showsthedistribution
of the average 58C class probabilities for each disease. The
average disease-class probabilities obtained during cross-validation
are 0.477 for the UKBS set and 0.561 for the 58C set. Both HT
(average58C classprobabilityof0.521,P<10−5)andBD(average
58C class probability of 0.514, P-value of 0.0002) are closer to the
58C control set, whereas both RA(average 58C class probability of
0.487, P<10−5) and CAD (average 58C class probability of 0.489,
P-value of 0.0003) are closer to the UKBS control set.
Giventhedifferencesbetweenthecontrolsets,andtheunexpected
similarities between control sets and diseases, we are interested in
verifying that the performance of the disease classiﬁers used in the
analysis is not an artifact caused by these differences. We therefore
train two new classiﬁers for each disease, one using only UKBS as
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Fig.4. Distributionoftheclassprobabilitiesforthecontrol–controlclassiﬁer
distinguishing the UKBS control set from the 58C control set. The two
histograms show the distribution of the 58C class probability of the
individuals,respectively,intheUKBS controlset(top)andinthe58C control
set(bottom),ascomputedduringcross-validation.Theredlinesrepresentthe
average class probabilities, and the black line indicates the 0.5 probability
cut-off used for binary classiﬁcation. The plot in between the histograms
shows the average disease-class probabilities of all seven other diseases on
the interval between the average class probabilities of the two control sets.
control set, and one using only 58C as control set. The performance
of these classiﬁers for T1D and RA is shown in Table 2, and is
similar to the performance of the classiﬁers that use both control
sets together. For the remaining diseases (including HT and BD),
the classiﬁers using only one of the control sets do not achieve
a classiﬁcation error below the baseline error, most likely due to
the smaller training set (i.e. overﬁtting). For each of the classiﬁers
for T1D and RA, we compute the average disease-class probability
for the other six diseases as well as the unused control set. The
similarities between the two diseases are signiﬁcant in all four
classiﬁers. Furthermore, the average disease-class probability of the
unused control set is similar to the average disease-class probability
of the other ﬁve diseases, and not signiﬁcantly closer to T1D or RA.
Therefore, we can conclude that the results obtained using the T1D
andRAclassiﬁersarenotduetodifferencesbetweenthecontrolsets.
Furthermore, the results using a single control set provide further
evidence indicating that the classiﬁers do identify relevant features
of T1D and RA, respectively, rather than relevant features of the
control set.
4 DISCUSSION
In this work, we introduce a novel approach for identifying genetic
similarities between diseases using classiﬁers. We identify genetic
similarities between several diseases. In this section, we ﬁrst discuss
the implications of these ﬁndings. We then consider challenges in
the application of classiﬁers to GWAS data. Finally, we propose
possible extensions of this approach.
We identify a strong similarity between T1D and RA. Genetic
factors that are common to these two autoimmune diseases were
identiﬁed well before the advent of GWAS, and linked to the
HLA genes (Torfs et al., 1986, Lin et al., 1998). The original
WTCCC study (WTCCC, 2007) identiﬁes several genes that appear
to be associated with both diseases. We look at the classiﬁers
corresponding to these two diseases. The SNP with the highest
information gain in T1D is rs9273363, which is located on
chromosome 6, near MHC class II gene HLA-DQB1, and is also the
SNPthat is most strongly associated with T1D in the initial analysis
of the WTCCC data, with a P-value of 4.29×10−298 (Nejentsev
etal.,2007).Thisisthestrongestassociationreportedforanydisease
in the WTCCC study, which explains to a large extent why the
T1D classiﬁer so clearly outperforms the classiﬁers for the other
diseases. This SNPis also signiﬁcantly associated with RA(P-value
of 6.74×10−11). The SNP with the highest information gain in
RA is rs9275418, which is also part of the MHC region, and is
strongly associated with both RA (P-value of 1.00×10−48) and
T1D (P-value of 7.36×10−126). This shows that our approach is
able to recover a known result, and uses SNPs that have been found
to be signiﬁcantly associated with both diseases in an independent
analysis of the same data.
The similarity we identify between HT and BD is interesting,
since there does not appear to be previous evidence of a link
between the two diseases at the genetic level. However, a recent
study identiﬁed an increased risk of HT in patients with BD
compared with general population, as well as compared to patients
with schizophrenia in the Dannish population (Johannessen et al.,
2006). The WTCCC study only identiﬁed SNPs with moderate
association to HT (lowest P-value of 7.85×10−6) and a single
SNP with strong association with BD (P-value of 6.29×10−8).
The decision trees for both diseases use a large number of SNPs
that have a very weak association with the respective disease. Both
classiﬁershaveaclassiﬁcationerrorthatisclearlybelowthebaseline
error, and provide evidence of similarity between the two diseases.
This indicates that our classiﬁer-based approach is able to use the
weak signals of a large number of SNPs to identify evidence for
similaritiesthatwouldbemissedbycomparingonlySNPsthatshow
moderate or strong association with the diseases. Further analyzes
are necessary to identify the nature and implications of the similarity
we ﬁnd between HT and BD, as well as the weaker similarity we
identiﬁed between these two diseases and T1D.
We also show that we can train a classiﬁer that can distinguish
the two control sets, and we use it to identify diseases that are
more similar to one of the control set than the other. This is not an
unexpected ﬁnding, since SNPs that were strongly associated with a
controlsetwereidentiﬁedanddiscardedintheWTCCCstudy.These
SNPs were also removed in the preprocessing step of our study, and
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the results we obtain when trying to distinguish the two control sets
therefore show that the decision tree classiﬁer is able to achieve a
classiﬁcation error below the baseline error even though the SNPs
withthestrongestassociationcouldnotbeusedbytheclassiﬁer.The
similarities between some diseases and one of the control sets can
most likely be explained by some subtle data quality issue. During
quality control, the authors of the WTCCC study found several
hundreds of SNPs in which some datasets exhibited a particular
probe intensity clustering [see the Supplementary Material of the
original WTCCC study (WTCCC, 2007) for details]. This particular
patternwasalwaysobservedin58C,BD,CD,HT,T1D,T2D,butnot
in UKBS, RA and CAD. This matches the result obtained using our
classiﬁer-basedapproach,inwhichRAandCADwerepredictedtobe
most similar to UKBS, and could therefore be a possible explanation
of the similarities we ﬁnd.
Whilewedoﬁndseveralinterestingsimilaritiesbetweendiseases,
we also observe that training a classiﬁer that distinguishes between
individuals with a disease and controls using SNP data poses
numerous challenges.The ﬁrst is that whether someone will develop
a disease is strongly inﬂuenced by environmental factors. The
genetic associations that can be identiﬁed using GWAS are only
predispositions, and it is therefore likely that some fraction of
the control set will have the predispositions, but will not develop
the disease. Furthermore, depending on the level of screening, the
disease might be undiagnosed in some control individuals, and
individuals that are part of a disease set might have other diseases
as well. This is especially true for high-prevalence diseases like HT.
Obtaining good classiﬁer performance by itself is not, however,
the main goal of our approach. We show that we can ﬁnd
similarities even when the classiﬁer performance only shows small
improvements compared with the baseline error. In this work, we
focus on the comparison approach, not on developing a classiﬁer
specially suited for the particular task of GWAS classiﬁcation.
We use decision trees because they are a simple, commonly used
classiﬁcation algorithm.
Thisworkshowsthatclassiﬁerscanbeusedtoidentifysimilarities
between diseases.This novel approach can be expanded into several
directions. First, classiﬁcation performance can be potentially
improved by using a different generic classiﬁer, or by developing
classiﬁers that do take into account the speciﬁc characteristics of
SNP data. Second, further analysis methods need to be developed
in order to analyze the trained classiﬁers, and identify precisely the
SNPs that do lead to the similarities this approach detects. Such
a methodology would be useful, for example, to further analyze
the putative similarity between HT and BD. Third, building on
the fact that our approach considers the whole genotype of an
individual, it could be possible to identify subtypes of diseases, and
clusterindividualsaccordingtotheirsubtype.Finally,modifyingthe
approachtoallowtheintegrationofstudiesperformedinpopulations
of different origins or using different genotyping platforms would
allow the comparison of a larger number of diseases.
Our approach identiﬁes similarities between the genetic
architecture of diseases.This is, however, only one of the many axes
along which disease similarities could be described. In particular,
both genetic and environmental factors interact in diseases, and
the genetic architecture for two diseases could be similar, but
the environmental triggers could be different, leading to low co-
occurrence. There is therefore a need for methods that integrate
similarities of different kinds that were identiﬁed using different
measurement and analysis modalities. An example of such an
approach is the computation of disease proﬁles that integrate both
environmental ethiological factors and genetic factors (Liu et al.,
2009).
5 CONCLUSION
GWAS have been used to identify candidate loci likely to be linked
to a wide variety of diseases. In this article, we introduce a novel
approach that allows identifying similarities between diseases using
GWAS data. Our approach is based on training a classiﬁer that
distinguishes between a reference disease and a control set, and
then using this classiﬁer for comparing several query diseases to
the reference disease. This approach is based on the classiﬁcation
of individuals using their full genotype, and is thus different from
previous work in which the independent statistical signiﬁcance of
each SNP is used for comparing diseases.
We apply this approach to the genotype data of seven common
diseases provided by the WTCCC, and show that we are able
to identify similarities between diseases. We replicate the known
ﬁnding that there is a common genetic basis for T1D and RA, ﬁnd
strong evidence for genetic similarities between BD and HT, as well
as evidence for genetic similarities between T1D and both BD and
HT. We also ﬁnd similarities between one of the control sets used
in the WTCCC (UKBS) and two disease sets, RA and CAD. This
similarity can possibly be a consequence of the subtle differences
in genotyping quality that were observed during the initial quality
control performed by the WTCCC.
Our results demonstrate that it is possible to use a classiﬁer-
based approach to identify genetic similarities between diseases,
and more generally between multiple phenotypes. We expect that
this approach can be improved by using classiﬁers that are more
speciﬁcally tailored for the analysis of GWAS data, and by the
integration of a larger number of disease phenotypes. The ability
to compare similarities between diseases at the whole-genome level
will likely identify many more currently unknown similarities.
Genetic similarities between diseases provide new hypotheses to
pursue in the investigation of the underlying biology of the diseases,
andhavethepotentialtoleadtoimprovementsinhowthesediseases
are treated in the clinical setting.
6 DATA
We use the individual genotypes provided by the WTCCC. These genotypes
come from a GWAS (WTCCC, 2007) of seven common diseases:T1D,T2D,
CAD, CD, BD, HT, and RA. The data consist of a total of 2000 individuals
per disease and 3000 shared controls, with 1500 control individuals from
the 1958 British Birth Cohort (58C control set) and 1500 individuals from
blood donors recruited speciﬁcally for the project (UKBS control set).
The genotyping of 500568 SNPs per individual was performed using the
Affymetrix GeneChip 500K Mapping Array Set. In the original analysis of
this dataset by the WTCCC, a total of 809 individuals and 31011 SNPs
that did not pass quality control checks are excluded. In addition, SNPs that
appear to have a strong association in the original study have been manually
inspected for quality issues, and 578 additional SNPs were removed. In this
work,weexcludeallindividualsandSNPsthatwereexcludedintheWTCCC
study, as well as an additional 9881 SNPs that do not appear in the WTCCC
summary results.
One concern with these quality control steps is the identiﬁcation of SNPs
for which the genotype calling is of poor quality. In the WTCCC study, this
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is done after the analysis, which makes it possible to visually inspect the
small subset of SNPs that are potentially signiﬁcant. In a classiﬁer-based
approach, it is impractical to perform any kind of visual inspection, and
we must try to minimize the errors due to genotype calling prior to the
analysis. The WTCCC study only uses genotype calls made by a custom
algorithm, Chiamo (Marchini et al., in preparation), but the genotype calls
made using the standard Affymetrix algorithm BRLMM are also available.
While the study does show that Chiamo has, on average, a lower error rate
than BRLMM, there are SNPs that are discarded during the quality control
process that show errors in the genotype calls made by Chiamo. We use the
two genotype sets to create a consensus dataset in which the genotype of a
givenindividualatagivenSNPisusedonlyifthereisagreementbetweenthe
call made by Chiamo and the call made by BRLMM, and is considered to be
unknown if the calls are different. This approach individually considers the
callmadeforeveryindividualateverySNP,anddoesnotdiscardentireSNPs.
The handling of SNPs that have a high proportion of unknown genotypes is
lefttotheclassiﬁcationalgorithm,andwillbediscussedinthecorresponding
section. While this approach does reduce the errors in genotype calling, this
comesatthecostofdiscardingcasesinwhichChiamoisrightbutBRLMMis
not. Overall, the frequency of unknown genotypes is 2% using the consensus
approach, compared with 0.65% using Chiamo and 0.74% using BRLMM.
Furthermore, BRLMM genotype calls are entirely missing for a total of 184
individuals, which are thus excluded from our study.
After performing these preprocessing steps, the data set used in this study
consists of 459075 SNPs measured in 2938 control individuals (58C: 1480,
UKBS: 1458), 1963 with T1D, 1916 individuals with T2D, 1882 individuals
with CAD, 1698 individuals with CD, 1819 individuals with BD, 1952
individuals with HT and 1834 individuals with RA.
7 METHODS
In this section, we ﬁrst formally deﬁne the classiﬁcation task that is central
to our approach, then describe the speciﬁc classiﬁer we use in this work
and how we evaluate its performance, and ﬁnally describe how we use the
classiﬁcation results to infer relationships between diseases.
7.1 Classiﬁcation Task
The data consist of a list of individuals i, a list of SNPs s∈S, and the
measurement of the genotype g(s,i) of individual i at SNP s. We use
Gi={g(1,i),...,g(|S|,i)} to denote the genotype of individual i at all the
SNPs in the study. The genotype measurement is a discrete variable which
can take four values: homozygote for the major allele, homozygote for the
minor allele, heterozygote and unknown: g(s,i)∈{maj,min,het,unk}. Each
individual belongs to one of several disease sets, or to the control set. For
the WTCCC data used in this work, we have seven disease sets: T1D, T2D,
CAD, CD, BD, RA, HT, and we use the union of the 58C and UKBS sets as
control set.
For each disease d, we train a classiﬁer that distinguishes between that
disease set and the controls. The individuals that are not part of these sets
are ignored during the training of this classiﬁer. For each individual i used
during training, a binary class variable ci indicates whether the individual
belongstothediseaseset(ci==disease)ortothecontrolset(ci==control).
The supervised classiﬁcation task consists of predicting the class ci of an
individual i given its genotype Gi. In this work, we use a decision tree
classiﬁer, but any algorithm able to solve this classiﬁcation task can be easily
integrated into our analysis pipeline.
7.2 Decision trees
In this section, we describe the decision tree classiﬁer (Breiman et al., 1984).
We use cross-validation in order to train the classiﬁer, prune the trained
decision tree and evaluate its performance on distinct sets of individuals.
We train a decision tree T by recursively splitting the individuals in each
node using maximum information gain for feature selection. We use binary
categorical splits, meaning that we ﬁnd the best rule of the form g(s,i)==γ,
where γ ∈{maj,min,het}. Binary splits make it possible to handle cases in
which only one of the three possible genotypes is associated with the disease
withoutunnecessarilysplittingindividualsthathavethetwoothergenotypes.
Unknown values are ignored when computing information gain. This is
necessary since there is a correlation between the frequency of unknown
valuesandthequalityofthegenotyping,whichinturnisvariablebetweenthe
different datasets. Counting unknown values during training could therefore
lead to classiﬁers separating the two sets of individuals based on data quality
differences, rather than based on genetic differences. However, if a large
number of measurements are unknown for a given SNP, the information
gain for that SNP will be biased. This is particularly true if the fraction of
unknowns is very different between the cases and the controls. In order to
avoid this situation, we discard all SNPs that do have >5% of unknown
genotypes amongst the training individuals in the node we are splitting. In
each leaf node L, we compute the fraction fL of training individuals in that
node of that are part of the disease class: fL=

i∈L(ci==disease)
|L| .
In order to choose a pruning algorithm, we compare the cross-validation
performance obtained using Cost-Complexity Pruning (Breiman et al.,
1984), Reduced Error Pruning (Quinlan, 1986), as well as a simple approach
consisting of limiting the tree depth. We ﬁnd that Reduced Error Pruning
outperforms Cost-Complexity Pruning, and performs similarly well than
limiting the tree depth, but results in smaller decision trees. We therefore use
Reduced Error Pruning, which consists of recursively eliminating subtrees
that do not improve the classiﬁcation error on the pruning set (which only
contains individuals that were not used during training).
The classiﬁcation of an individual i using a decision tree T is done by
traversing the tree from the root towards a leaf node L(i) according to the
genotypeoftheindividualwhichisclassiﬁed.IffL(i) >0.5,thentheindividual
is classiﬁed as disease, else the individual is classiﬁed as control. We can
consider the decision tree T as a high-level statistical model of the difference
between the disease and the control sets. Under this model, the fraction fL(i)
represents the conditional probability of individual i to be part of the disease
class given its genotype: PT(ci==disease | Gi)=fL(i). This value is the
disease-class probability of individual i. In order to compute the fractions fL
over sufﬁciently large numbers of individuals, we further prune our tree to
only have leaf nodes containing at least 100 training individuals. The beneﬁt
of using this probability rather than the binary classiﬁcation is that it allows
to distinguish leaf nodes in which there are mainly training individuals from
one class from those in which both classes are almost equally represented.
In order to assess the performance of our classiﬁer, we perform 5-fold
cross-validation. We start by separating the data into ﬁve random sets
containing20%oftheindividualseach.AdecisiontreeT istrainedusingfour
ofthesesets,whileonesetisreservedforpruningandtesting.Theunusedset
is split randomly into two equal sets. The ﬁrst of these sets is used to obtain
pruned tree T  from tree T, and the individuals in the second set are used
to evaluate the performance of tree T . The last step is then repeated using
the second set for pruning, and the ﬁrst for testing. Finally, we repeat the
training and evaluation four more times, each time leaving out a different set
for pruning and testing. This ensures that for every individual in our dataset,
there is one pruned decision tree for which the individual was used neither
for training nor for pruning. We can therefore evaluate the performance of
the classiﬁer on unseen data. We can also compute the average disease-class
probability p(C) of the control individuals, and the average disease-class
probabilityp(d)oftheindividualswithdiseased.Thedifference p between
those two probabilities indicates how well the classiﬁer is able to distinguish
controls from diseases. We use the cross-validation results to compare the
performance of the classiﬁer against a baseline classiﬁer which simply
assigns the most frequent label amongst the training set to all individuals.
Classiﬁers that do not outperform this baseline classiﬁer, or for which the
difference  p is small, are not used to identify similarities between diseases.
Given the cross-validation scheme used, we end up training not one, but
several possibly distinct decision trees. Rather than arbitrarily choosing one,
we use the set Td of all decision trees trained during cross-validation for a
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given disease d. In order to classify a new individual i, we ﬁrst classify i
usingeachclassiﬁerindependently,andthenreturntheaverageclassiﬁcation.
Similarly,weaveragetheresultsofindividualclassiﬁerstoobtaintheaverage
disease-classprobability:PTd(ci==disease|Gi)=

T∈Td PT(ci==disease | Gi)
|Td| .
7.3 Identifying similarities
Once a classiﬁer has been trained to distinguish the set of individuals with
reference disease d from the control set, we can use it to identify diseases
thataresimilartodiseased.Usingtheclassiﬁer,wecancomputethedisease-
class probability of an individual with a query disease d . In order to be able
to compare diseases, we are interested in computing the average disease-
class probability of all individuals in d : p(d )=

i∈d  PTd (ci==disease | Gi)
|d | .W e
expect this average probability to be in, or close to the interval between p(C)
and p(d), which were the averages computed on, respectively, the control set
and the disease set d during cross-validation. If p(d ) is close to p(C), then d 
is not very different from the control set, whereas a value p(d ) that is close
to p(d) indicates similarity between the two diseases. Using this method, we
can compare all query diseases to the reference disease d, and identify if
there are diseases that are more similar to d than others.
If we ﬁnd that a query disease d  is closer to reference disease d than the
other query diseases, then we need to assess the signiﬁcance of this ﬁnding.
In order to do so, we randomly sample a set r of individuals from all the
disease sets except d, such that r is of the same size as d , and compute p(r).
We repeat this procedure 10000 times. The fraction of random samples r
for which p(r)≥p(d ) indicates how often a random set of individuals would
obtain a probability of being part of the disease-class at least as high as the
set d , and is therefore a P-value indicating how signiﬁcant the similarity
between d  and d is.
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